*Guest blog by LimestoneGrey. If you would like to submit a guest blog please email [email protected].
Protecting Your Business in a Higher-Scrutiny R&D Tax Landscape
R&D tax relief remains a valuable incentive for medtech and life sciences companies investing in genuine scientific and technological advancement. Whether a business is developing medical devices, diagnostic platforms, digital health technologies, therapeutics, clinical tools or advanced healthcare systems, R&D tax relief can provide vital support.
A Changing R&D Tax Relief Landscape
HMRC has significantly…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Eva Font, Regulatory and Start-up Director – Pivotal
How sponsors can leverage both the EU Clinical Trials Regulation and UK’s reformed framework to achieve cost efficiencies, faster timelines, and stronger regulatory positioning.
EXECUTIVE SUMMARYThe post-Brexit regulatory landscape has created a unique — and frequently underutilized — opportunity for…
*Guest blog by Romy Frow at Travel Counsellors. If you would like to submit a guest blog please email [email protected].
Business travel has always had a lot of moving parts: flights, hotels, ground transport, budgets and policies. Today, it also means navigating constantly changing geopolitics, airline schedule changes and sudden disruptions, such as the recent events and airspace restrictions in the Middle East.
If you are responsible for multiple travellers, complex itineraries or mission-critical journeys, the stakes are simply too high to leave travel to chance or rely on ad hoc…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Transforming Patient Care Through Innovation
Executive Summary
Drug-resistant epilepsy (DRE) affects approximately 15–16 million people worldwide1 — roughly 30% of all individuals with epilepsy. Despite optimal pharmacological therapy, patients experience profound impacts on safety, independence, cognitive function, and survival. The emergence of novel therapeutic agents…
By Monalisa Breazu, Learning & Development Administrator
We recently hosted a seminar on business lead generation from events that sparked a lot of honest conversation around something many businesses know all too well: being busy is not always the same as generating real opportunities.
You can attend the right events, have plenty of conversations, collect a handful of business cards and still come away wondering why none of it turned into actual leads.
One of the strongest themes from the session was that successful lead generation is rarely about saying more. It is usually about saying…
by Philippa Clark, Director of Business Development, One Nucleus
I recently attended a women‑led science event, and it’s one of those occasions that stays with you for reasons you don’t fully expect. It wasn’t a single presentation or statistic that caught my attention, but a theme that kept resurfacing throughout the day and gradually shifted how I was thinking about the whole topic.
For a long time, conversations about women’s health have understandably focused on what’s missing: the gaps in diagnosis, the lack of funding, and the treatments that don’t reflect the realities of women’s…
by Philippa Clark, Director of Business Development, One Nucleus
I have been thinking a lot about One Nucleus’ recent visit to the Flanders-UK Partnering in Ghent, Belgium, partly because it was such a great couple of days, but mostly because it reminded me how energising it can be to step into another ecosystem and see how people are approaching similar challenges from a different perspective. The trip was organised with VIB and Biovia, and from the moment we arrived, it felt as though we were stepping into a community that genuinely wanted to connect, share and learn alongside us.
What I…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
The AI revolution in Pharmaceutical R&D is transitioning from experimental curiosity to operational necessity. This transformation is supported by quantifiable operational improvements: AI-enabled discovery workflows have shown the potential to reduce early discovery timelines by up to 40% and costs by approximately 30% for complex targets [1].
The strategic role of…
For many Life Sciences companies, R&D tax relief has long been viewed as a mechanism for recovering cost; an incentive aligned with innovation, growth, and scientific ambition.
That framing is no longer sufficient.
Over the past 18–24 months, we have seen a clear shift in how R&D claims in the Life Sciences sector are reviewed and challenged by HMRC. The focus has moved decisively away from the size of a claim and towards its technical credibility, evidential support, and internal consistency.
For finance leaders and R&D teams alike, this marks an important change in…
As we approach a new financial year, five months on from the launch of the Charities Aid Foundation's latest Corporate Giving Report, its message remains powerful: corporate giving is declining, yet it remains a central pillar to responsible business.
You may be wondering who the Charities Aid Foundation are? The Charities Aid Foundation (CAF) are a global charity working with individual and corporate donors to turn their generosity, connection to a cause and ambition, into purposeful change. We help businesses, including those in the life sciences sector, to give to charities around the…